BiotechTube

GRNOPC1

Phase 1Completed
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Spinal Cord Injury

Conditions

Spinal Cord Injury

Trial Timeline

Oct 1, 2010 → Jul 1, 2013

NCT ID
NCT01217008

About GRNOPC1

GRNOPC1 is a phase 1 stage product being developed by Lineage Cell Therapeutics for Spinal Cord Injury. The current trial status is completed. This product is registered under clinical trial identifier NCT01217008. Target conditions include Spinal Cord Injury.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01217008Phase 1Completed

Competing Products

20 competing products in Spinal Cord Injury

See all competitors
ProductCompanyStageHype Score
SUN13837 injection + PlaceboDaiichi SankyoPhase 2
52
Placebo + Reldesemtiv 150 mg + Reldesemtiv 450 mgAstellas PharmaPhase 2
52
Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor CellsSun PharmaceuticalPhase 2
52
Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor CellsSun PharmaceuticalPhase 1
33
ElezanumabAbbViePre-clinical
23
Elezanumab + PlaceboAbbViePhase 2
52
Ropivacaine + BupivacaineAstraZenecaPhase 3
77
Onasemnogene Abeparvovec-xioiNovartisPhase 1
33
ZolgensmaNovartisPre-clinical
23
BVS857 + PlaceboNovartisPhase 2
52
AVXS-101NovartisPhase 1
33
Onasemnogene Abeparvovec-xioiNovartisPhase 3
77
Onasemnogene Abeparvovec-brveNovartisApproved
85
Onasemnogene Abeparvovec-xioiNovartisPre-clinical
23
Onasemnogene Abeparvovec-xioiNovartisPhase 3
77
branaplamNovartisPhase 1/2
41
Onasemnogene Abeparvovec-xioiNovartisPhase 3
77
onasemnogene abeparvovecNovartisPhase 3
77
onasemnogene abeparvovec-xioiNovartisPhase 3
77
RisdiplamRochePhase 1
33

Other Products from Lineage Cell Therapeutics

AST-OPC1Phase 1/2
33
OPC1Phase 1
25